Which is better, GMAB or NNNN?

On the Buffett-Fit framework, Anbio Biotechnology Class A Ordinary Shares (NNNN) currently grades higher than GMAB — 58/100 (C grade) vs 65/100 (C). That said, "better" depends on which framework you trust — GMAB wins on Warren Buffett and Joel Greenblatt; NNNN wins on Benjamin Graham, Philip Fisher, Peter Lynch, Charlie Munger, and Terry Smith. The full pillar breakdown is on this page.

Should I buy GMAB or NNNN?

This page is an educational comparison, not investment advice. Both GMAB and NNNN are graded against the same Buffett 5-pillar framework (moat, earnings durability, management quality, financial health, valuation) plus six other documented investor frameworks. Read the side-by-side breakdown to see which one matches the criteria you care about most — and always do your own research before making any investment decision.

Is GMAB better than NNNN for value investing?

On the Buffett-style value-investing framework, NNNN currently grades higher — 65/100 vs 58/100, a 7-point gap. The gap is driven by which pillars each stock passes; the table on this page shows moat, durability, management, financial health, and valuation side-by-side.

What's the difference between GMAB and NNNN on Warren Buffett's framework?

Both stocks are evaluated on the same five pillars: economic moat (durable competitive advantage), earnings durability (consistent profitability), management quality (capital allocation), financial health (conservative balance sheet), and valuation (margin of safety). GMAB currently scores 65/100 (C grade); NNNN scores 58/100 (C grade). The "Where each wins" section on this page breaks down which pillar each stock dominates.

Which has the stronger moat, GMAB or NNNN?

Moat strength is one of the five pillars in the Buffett-Fit score on this page. GMAB and NNNN are each scored on ROIC sustainability, gross-margin durability, and qualitative signals like brand strength, switching costs, network effects, and regulatory barriers. The pillar breakdown on this page shows the moat sub-score side-by-side so you can see which one has the more durable competitive advantage.

Which is more undervalued, GMAB or NNNN?

Valuation is one of the five Buffett-Fit pillars on this page. Both stocks are scored on owner-earnings yield, price-to-intrinsic-value vs the underlying compounding rate, and the margin of safety relative to a conservative DCF. The valuation sub-score in the table below tells you which one currently trades at a more attractive price relative to its underlying business quality.

Are GMAB and NNNN both Healthcare stocks?

Yes — both Genmab A/S (GMAB) and Anbio Biotechnology Class A Ordinary Shares (NNNN) operate in the Healthcare sector. That makes this a direct sector-peer comparison, which is the apples-to-apples way to use the Buffett-Fit framework: the score weighs each stock against its sector's specific quality and valuation benchmarks (sector-relative bonus), so the cross-stock comparison isn't distorted by inter-sector base-rate differences.

Is this GMAB vs NNNN comparison investment advice?

No. This page is an educational pattern-match against documented public frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith), not personalised investment advice. The scores reflect how closely each stock matches each framework's documented criteria — they are not buy/hold/sell recommendations. Always do your own research and consult a licensed financial adviser for personalised advice.

Stock comparison

Genmab A/S

Anbio Biotechnology

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

GMAB

Genmab A/S

Market cap

$16.47B

Sector

Healthcare

NNNN

Anbio Biotechnology

Market cap

$1.43B

Sector

Healthcare

Overall winner

Anbio Biotechnology NNNN

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Fit scores by strategy

Strategy	GMAB	NNNN	Winner
Warren Buffett	65C	58C	GMAB
Benjamin Graham	64C	87A	NNNN
Philip Fisher	48D	89A	NNNN
Peter Lynch	25F	95A	NNNN
Joel Greenblatt	76B	36D	GMAB
Charlie Munger	68C	73C	NNNN
Terry Smith	71C	72C	NNNN

Side-by-side metrics

Metric	GMAB	NNNN
Market cap	$16.47B	$1.43B
P/E (TTM)	6.2x	171.9x
EV/EBIT	12.0x	212.9x
ROIC (TTM)	43.78%	21.48%
Gross margin	93.88%	87.06%
Net margin	18.23%	73.75%
Revenue CAGR 5y	-18.45%	18.21%
EPS CAGR 5y	-23.48%	58.42%
Debt / Equity	0.1x	-
Dividend yield	0.0%	0.0%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

GMAB leads on

P/E (TTM)6.2xvs 171.9x+96%
EV/EBIT12.0xvs 212.9x+94%
Market cap$16.47Bvs $1.43B+91%
ROIC (TTM)43.78%vs 21.48%+51%

NNNN leads on

Revenue CAGR 5y18.21%vs -18.45%+199%
EPS CAGR 5y58.42%vs -23.48%+140%
Debt / Equity-vs 0.1x+100%
Net margin73.75%vs 18.23%+75%

More like GMAB

GMAB vs IDXX GMAB vs 7741.T GMAB vs SUNPHARMA.NS GMAB vs LMAT GMAB vs HALO GMAB vs MTD

More like NNNN

NNNN vs IDXX NNNN vs 7741.T NNNN vs SUNPHARMA.NS NNNN vs LMAT NNNN vs HALO NNNN vs MTD

Read the full Buffett-Brain analysis for GMAB Read the full Buffett-Brain analysis for NNNN

Related on invest-like

Strongest Moat Highest ROIC Warren Buffett strategy Economic Moat

Key terms in this analysis

ROIC Free Cash Flow (FCF)Economic Moat P/E Ratio Margin of Safety Quality Score

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.

Stock comparison

Genmab A/S

Anbio Biotechnology

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

GMAB

Genmab A/S

Market cap

$16.47B

Sector

Healthcare

NNNN

Anbio Biotechnology

Market cap

$1.43B

Sector

Healthcare

Overall winner

Anbio Biotechnology NNNN

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Fit scores by strategy

Strategy	GMAB	NNNN	Winner
Warren Buffett	65C	58C	GMAB
Benjamin Graham	64C	87A	NNNN
Philip Fisher	48D	89A	NNNN
Peter Lynch	25F	95A	NNNN
Joel Greenblatt	76B	36D	GMAB
Charlie Munger	68C	73C	NNNN
Terry Smith	71C	72C	NNNN

Side-by-side metrics

Metric	GMAB	NNNN
Market cap	$16.47B	$1.43B
P/E (TTM)	6.2x	171.9x
EV/EBIT	12.0x	212.9x
ROIC (TTM)	43.78%	21.48%
Gross margin	93.88%	87.06%
Net margin	18.23%	73.75%
Revenue CAGR 5y	-18.45%	18.21%
EPS CAGR 5y	-23.48%	58.42%
Debt / Equity	0.1x	-
Dividend yield	0.0%	0.0%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

GMAB leads on

P/E (TTM)6.2xvs 171.9x+96%
EV/EBIT12.0xvs 212.9x+94%
Market cap$16.47Bvs $1.43B+91%
ROIC (TTM)43.78%vs 21.48%+51%

NNNN leads on

Revenue CAGR 5y18.21%vs -18.45%+199%
EPS CAGR 5y58.42%vs -23.48%+140%
Debt / Equity-vs 0.1x+100%
Net margin73.75%vs 18.23%+75%

More like GMAB

GMAB vs IDXX GMAB vs 7741.T GMAB vs SUNPHARMA.NS GMAB vs LMAT GMAB vs HALO GMAB vs MTD

More like NNNN

NNNN vs IDXX NNNN vs 7741.T NNNN vs SUNPHARMA.NS NNNN vs LMAT NNNN vs HALO NNNN vs MTD

Read the full Buffett-Brain analysis for GMAB Read the full Buffett-Brain analysis for NNNN

Related on invest-like

Strongest Moat Highest ROIC Warren Buffett strategy Economic Moat

Key terms in this analysis

ROIC Free Cash Flow (FCF)Economic Moat P/E Ratio Margin of Safety Quality Score

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.